Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Reuben ThomasGladstone Institutes, San Francisco, CA, USA.
Douglas ArnesonBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA.
Pavitra RoychoudhuryDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-4567-8232
Atul J ButteBakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7433-2740
Joseph K WongSan Francisco Veterans Affairs (VA) Medical Center and University of California, San Francisco, CA, USA.ORCID 0000-0001-9896-0605
Rebecca HohDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, CA, USA.
Steven G DeeksDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0001-6371-747X
Sulggi A LeeZuckerberg San Francisco General Hospital and the University of California, San Francisco, CA, USA.ORCID 0000-0003-1560-2250
Nadia R RoanGladstone Institutes, San Francisco, CA, USA. nadia.roan@ucsf.edu.ORCID 0000-0002-5464-1976
Steven A YuklSan Francisco Veterans Affairs (VA) Medical Center and University of California, San Francisco, CA, USA. steven.yukl@ucsf.edu.ORCID 0000-0002-4578-9872
Funding
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
HOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Lishomwa C Ndhlovu, Melanie Maria Ott · 2021 to 2026
$32.2M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6M
The heterogeneous HIV expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to reboundP01AI169606 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Steven A Yukl · 2022 to 2026
$9.3M
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodesR01DK120387 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI LICHTERFELD, MATHIAS, YUKL, STEVEN A · 2019 to 2023
$4.1M
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologiesR01AI147777 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2019 to 2022
$3.8M
Multiomics characterization, induction, and elimination of the HIV gut reservoirR01DK131526 · NIDDK · J. DAVID GLADSTONE INSTITUTES · PI Nancie Marie Archin, Nadia R Roan · 2022 to 2026
$3.7M
Targeting the transcriptionally-active reservoir to reduce chronic inflammation in aged people with HIVR01AI183286 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Melanie Maria Ott, Nadia R Roan · 2024 to 2026
$2.7M
Understanding and targeting the HIV-expressing reservoir to reduce immune activationR01AI183666 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT, Steven A Yukl · 2024 to 2026
$2.4M
Understanding HIV latency reversal and clearance of infected cells in vivoR01AI132128 · NIAID · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WONG, JOSEPH K, YUKL, STEVEN A · 2017 to 2021
$1.9M
Direct and Indirect Targeting of HIV Tat for Selective RNA Degradation and Protein SuppressionR01AI194343 · NIAID · UNIVERSITY OF MELBOURNE · PI Sushama Telwatte · 2025 to 2026
$820k
California HIV/AIDS Research Program (CHRP) BB19-SF-009/A135087NIAID NIH HHS P01 AI169606NIAID NIH HHS R01 AI183666NIAID NIH HHS R01 AI194343NIDDK NIH HHS R01 DK120387U.S. Department of Health & Human Services | National Institutes of Health (NIH) P01AI169606U.S. Department of Health & Human Services | National Institutes of Health (NIH) P30AI027763U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI132128U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI147777U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI183286U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI183666U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI194343U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01DK120387U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01DK131526U.S. Department of Health & Human Services | National Institutes of Health (NIH) R21AI170166U.S. Department of Health & Human Services | National Institutes of Health (NIH) UM1AI164559U.S. Department of Health & Human Services | National Institutes of Health (NIH) UM1AI164560U.S. Department of Health & Human Services | National Institutes of Health (NIH) UM1AI164567
6 · The paper itself
Abstract
HIV-transcribing cells can perpetuate chronic inflammation in ART-suppressed people with HIV (PWH) and likely contribute to viral rebound after ART interruption. However, these cells are difficult to study using single-cell RNA-seq (scRNA-seq) due to their low frequency and low levels of HIV transcripts, which are usually not polyadenylated. By spiking in capture sequences targeting conserved regions of HIV during scRNA-seq - a new method we call "HIV-seq" - we detect double the mean number of HIV reads per cell from PWH. HIV RNA+ cells are enriched among T effector memory cells during both viremia and ART suppression but exhibit a cytotoxic signature during viremia only. In contrast, HIV-transcribing cells from ART-suppressed timepoints exhibit a distinct anti-inflammatory signature involving elevated TGF-β and diminished IFN signaling. These findings demonstrate that HIV-seq is a useful tool to better understand the mechanisms by which HIV-transcribing cells can persist during ART.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
HIV-seq reveals gene expression differences between HIV-transcribing cells from viremic and suppressed people with HIV. · full record | OpenQuestion